Alleviant Medical, Inc., an Austin, TX-based medical device company developing a no-implant atrial shunt for heart failure, raised $90m in financing.
Led by Gilde Healthcare, the round also adds Omega Funds and includes participation from existing shareholders S3 Ventures, RiverVest Venture Partners, Vensana Capital, Longview Ventures, Gilmartin Capital, TMC Venture Fund, and undisclosed strategic investors.
The company intends to use the funds to conduct its second pivotal trial. The new pivotal trial, ALLAY-HFrEF, will be the first prospective sham-controlled trial focused on patients with heart failure and reduced ejection fraction (HFrEF) in the atrial shunt space.
Led by Adam Berman, CEO, Alleviant Medical is a medical device company developing minimally invasive therapies to treat heart failure, collaborating with the top leaders in cardiovascular medicine to advance patient care. The Alleviant System has been granted U.S. FDA Breakthrough Device designation for both major forms of heart failure.
The Alleviant System is an Investigational Device and is limited by federal (or U.S.) law to investigational use. Exclusively for clinical investigation.
FinSMEs
15/01/2025